Introduction
Ovarian cancer was ranked as one of the prevalently lethal gynecologic malignancies, and it was estimated that there is a global incidence of 22,440 new cases per year, with an incidence of 14,080 deaths annually. 1 Currently, the standard treatment for ovarian cancer consists of cytoreductive surgery and adjuvant chemotherapy. 2 Recent studies have examined platinum-containing chemotherapeutic drugs and targeted therapy, like poly(ADP-ribose) polymerase inhibitors, niraparib, veliparib, and rucaparib.
The human ovarian cancer cell lines (COV644, COV362, OV90, SKOV3, TOV112D, OVCAR4, A2780, and COV434, TOV21G) and normal ovarian epithelial cells (HOSEpiC) were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). HOSEpiC were cultured in Defined Keratinocyte-SFM (1×) (Invitrogen, Carlsbad, CA, USA). The ovarian cancer cell lines were cultured in Dulbecco's modified Eagle's medium (Invitrogen) with 10% fetal bovine serum (Gibco, Grand-Island, NY, USA) and 1% penicillin (100 U/mL) and streptomycin (100 µg/mL) at 37°C under 5% CO 2 incubator added.
Tissue specimens and patient information
This research was carried out on the paraffin-embedded tissues from 150 EOC patients and 10 freshly paired EOC tissues, which were diagnosed at Sun Yat-sen University Cancer Center between 2001 and 2010. The clinical characteristics of the 150 samples are recorded in Table 1 . The median follow-up time for the whole samples was 49.83 months (range from 3 to 178.2 months). The approval from Sun Yat-sen University Cancer Center Institutional Review Ethics Board was obtained (YB2017-037). Written informed consent was obtained from each patient, and the experiments involving human tissue samples were approved by the Institutional Review Ethics Board of Sun Yat-sen University Cancer Center.
Plasmids, infection, and transfection
Human KIF20A complementary DNA (cDNA) was polymerase chain reaction (PCR)-amplified by PCR forward: agatctGCCACCATGTCGCAAGGGATCCTTTC; reverse: gaattcTTAGTACTTTTTGCCAAAAG. To silence KIF20A, two siRNAs against KIF20A in pSuper-puro vector were obtained from Ribobio Inc (Guangzhou, Guangdong, China). The siRNA sequences are as follows: si-KIF20A-1 :5′-CTC-CGAGATGAAATTTGCA-3′; si-KIF20A-2 :5′-GGTCT-GTGGTACGCAAGAA-3′; Transfection was performed using Lipofectamine 3000 reagent (Invitrogen) in line with the manufacturer's instructions.
Rna extraction reverse transcription and real-time PCR
Total RNA was isolated from 10 freshly paired clinical samples and cell lines by using Trizol reagent (Invitrogen) based on the manufacturer's instructions. Then, we used RNase-free DNase to inhibit degradation. In line with the manufacturer's guidelines, we used Revert Aid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA) to synthesize cDNA from RNA (2 µg) obtained from each sample. The qPCR primer sequences were displayed as follows: KIF20A forward primer: 5′-TCAGAGCGCTGCAAAGATCA-3′; KIF20A reverse primer: 5′-CGGTTCTGCTGGTTTTGACG-3′; GAPDH forward primer: 5′-AGAGGCAGGGATGATGTTCTG-3′; and GAPDH reverse primer; 5′-AGAGGCAGGGATGAT- 
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Overexpression of kinesin family member 20a in epithelial ovarian cancer immunohistochemistry Immunohistochemistry (IHC) analysis was performed to detect KIF20A protein expression in 150 EOC patients. Briefly, all specimens were cut into 4-µm sections and baked at 60°C for 1 hour. We removed paraffin from these sections by using xylene, once in 10 minutes, twice. Then, these sections were treated in different ethanol solutions (100%, 100%, 95%, 90%, and 80%). Then, EDTA antigenic retrieval buffer and microwave were used to retrieve antigenic of the sections. In order to extinguish endogenous peroxidase activity, the samples were processed with 3% hydrogen peroxide in methanol. Then, 1% bovine serum albumin was selected to block nonspecific blinding. Subsequently, rabbit polyclonal anti-KIF20A antibody (1:600; Sigma; HPA036910) was used to incubate the sections overnight at 4°C. PBS served as the negative control. After washing, the clinical sections were processed with prediluted anti-rabbit secondary antibody (Abcam), followed by treatment with streptavidin-horseradish peroxidase complex (Sigma), and then soaked in 3-amino-9-ethylcarbazole. These sections were mounted in Crystal Mount after the processing of counterstaining with 10% Mayer's hematoxylin and dehydrating. The score of immunostaining was separately evaluated by two pathologists who were blinded to the clinical parameters. Evaluation of KIF20A protein expression and scores of immunostaining were assessed by two observers separately. The staining intensity of KIF20A was classified as follows: 0 (no staining), 1 (weak staining), 2 (moderate staining), and 3 (strong staining). The proportion of tumor cells was graded from 0 to 3: 0 (<10%), 1 (10%-50%), 2 (51%-75%), and 3 (>75%). The product of the proportion of tumor cells and staining intensity score was seen as the staining index. According to the methods of this evaluation, we assessed KIF20A expression in ovarian cancer samples by determining the staining intensity (SI), with scores of 0-9. The median SI of all ovarian cancer tissues was 4. Thus, we distinguished high and low KIF20A expressions by the following criteria: SI ≤4 was defined as tumors with low KIF20A expression; SI ≥6 was indicated as tumors with high KIF20A expression.
Transwell assay
Transwell chambers (8- ) were incubated in serum-free medium and then added to the upper chamber of transwell chambers. The lower chamber was added with 10% FBS culture medium. After incubation at 37°C for 24 hours, the cells in the upper chamber were transited into the lower surface. We used 4% paraformaldehyde and stained it with hematoxylin. Finally, we used microscope (Nikon Eclipse 80i) to count the cells (10 random 200 × fields per well). All experiments were conducted three times.
Wound healing assay
The ovarian cancer cells transfected vector KIF20A or KIF20A siRNA were seeded in six-well plates and grown until almost confluence in 24 hours, and then cultured in serum-free medium for 24 hours. We used a 200-µL pipette to scratch an artificial homogeneous wound of cell monolayers, followed by washing with PBS and cultured it in DMEM plus 10% FBS. Inverted microscope was used to measure the average distance between the edge and the center of the straight scratch at time points 0, 12, and 24 hours (with a 10× objective lens).
MTT assays
The sensitivity to cisplatin of EOC cells was measured using MTT assays followed by the manufacturer's instructions. Briefly, 4×10 3 cells were put on 96-well plates and cultured at 37°C overnight and treated with different cisplatin concentrations (3, 9, 27, 81, and 243 µm) for 48 hours. We added the MTT solution (20 µL; 5 mg/mL), and the plates were further incubated for 4 hours. At the end point, 200 µL DMSO was added to the plates in order to stabilize the product. The absorbance was measured at 570 nm. The IC50 values were analyzed using the GraphPad Prism ® six software.
annexin V/Pi assay 
Results

KiF20a expression was upregulated in ovarian cancer cell lines
To explore KIF20A expression in ovarian cancer, we detected KIF20A expression in different kinds of ovarian cancer cells (COV644, COV362, OV90, SKOV3, TOV112D, OVCAR4, A2780, COV434) and HOSEpiC at mRNA and protein levels. The results showed that KIF20A was elevated in all of the ovarian cancer cell lines compared with HOSEpiC (P<0.05; Figure 1A , B).
KiF20a expression in eOC and normal control tissues
The KIF20A expression of 10 paired fresh EOC tissues and the adjacent noncancerous tissues was examined at transcription and translation levels. As shown in Figure 2A -C, KIF20A expression was significantly upregulated in 10 ovarian cancer tissues compared with the paired noncancerous tissues (P<0.05). Next, we carried out IHC staining to detect the KIF20A protein expression level ( Figure 2D and Figure S1A ). The results were strongly consistent with the KIF20A protein expression examined by Western blotting. (Table 1) . KIF20A was mostly positioned in the nucleus and cytoplasm of the ovarian cancer cells. The expression of KIF20A was low or absent in normal ovarian tissues. The intensity of KIF20A staining increases sequentially from clinical stage I to IV ( Figure  3A ). As shown in Figure S2A -D, we conducted IHC staining in four histological types of EOC, including serous adenocarcinoma, mucoid adenocarcinoma, endometrial adenocarcinoma, and clear cell adenocarcinoma. Besides, the expression of KIF20A protein was stronger in recurrence group than in the nonrecurrence group ( Figure 3 ). We noted positive KIF20A protein expression in 40% (10/25), 38.89% (7/18), 66.26% (55/83), and 88.89% (8/9) stage I, II, III, and IV tumors, respectively (P<0.05, Table 2 ).
Quantitative IHC analysis suggested that mean optical density (MOD) value of KIF20A was obviously correlated with FIGO stages ( Figure 3B ) and was higher in recurrence group than in nonrecurrence group ( Figure 3D) 
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Overexpression of kinesin family member 20a in epithelial ovarian cancer serum CA125, CA199, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and β human choriogonadotropin (β-HCG) levels were not statistically significant (Table 3 ). These results indicate that KIF20A has an important impact on ovarian cancer recurrence and progression.
high KiF20a expression was obviously related with poor prognosis in eOC Survival analysis pointed that patients with KIF20A overexpression had a significantly shorter overall survival (OS) and disease-free survival than those with low KIF20A expression ( Figure 4A , B, log-rank, P<0.001). In the cohort, patients with elevated KIF20A expression had an obviously lower cumulative 5-year survival rate compared with those with low KIF20A expression (27.4% vs 84.0%, respectively; P<0.05). We also examined the prognostic value of KIF20A expression in subgroups stratified by tumor recurrence ( Figure 4C 
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Overexpression of kinesin family member 20a in epithelial ovarian cancer (P<0.001) could serve as important prognostic factors (Table 4) . Furthermore, multivariate Cox regression analysis showed that only KIF20A protein expression level (P=0.017) and tumor recurrence (P=0.009) were statistically significant ( Table 4) .
Overexpression of KiF20a facilitates the invasion and metastasis abilities of eOC cells
To further explore the function of KIF20A in the invasion and metastasis of EOC, we transiently transfected KIF20A cDNA and KIF20A-siRNA to A2780 cells and SKOV3 cells for 24 hours. Western blot assay was used to evaluate the efficiency ( Figure S1 ). As shown in Figure 5A -C, overexpression of KIF20A enhanced invasion ability of A2780 and SKOV3 cells, whereas silence of KIF20A remarkably reduced the invasive cell numbers. Furthermore, by using the wound healing assay, we found that the KIF20A-transduced EOC cells exhibit an increase in migration ability, while the KIF20A-silenced cells showed an inhibition in their migration ability ( Figure 5D , E). These data show that overexpression of KIF20A facilitates EOC cells' invasion and migration abilities compared with vector control cells.
KiF20a confers resistance to cisplatin in eOC cells
To further verify that KIF20A mediates ovarian cancer cells' chemoresistance, MTT/IC50 assay and Annexin V-FITC/ PI assay were performed on the indicated cells. MTT/IC50 assay indicated that the IC50 value for cisplatin was obviously raised in KIF20A-overexpression ovarian cancer cells, while it was decreased in KIF20A-silenced cells ( Figure 6A, B) . Consistently, we also found that the proportion of apoptotic cells in KIF20A-overexpression group treated with cisplatin was much lower compared with the control group, yet much higher in the KIF20A-silenced group ( Figure 6C ). Collectively, these results strongly suggest that KIF20A confers chemoresistance in EOC cells.
Discussion
Similar to our study, recent studies have reported that KIF20A is upregulated in several cancers. [11] [12] [13] [14] [15] Besides, significant 
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Overexpression of kinesin family member 20a in epithelial ovarian cancer evidence indicated that high expression of KIF20A promotes cell metastasis and proliferation in various types of cancers, indicating that overexpression of KIF20A is related to tumor progression. 14, 15, 17, 18 As far as we know, this is the first exploration that KIF20A overexpression is closely related to unfavorable prognosis and clinical characteristics, especially tumor recurrence, in EOC. We found that the upregulation of KIF20A occurred at both mRNA and protein levels in EOC tissues in comparison with normal ovarian tissues. High KIF20A expression was closely correlated with FIGO stage, intraperitoneal metastasis, LN metastasis, vital status at last follow-up, tumor recurrence, intraperitoneal recurrence, ascites with tumor cells, and drug resistance. Patients with upregulated KIF20A expression were more likely to experience tumor recurrence during treatment, which is an important cause of poor prognosis of EOC. Univariate and multivariate regression analyses revealed that KIF20A expression can serve as an independent prognostic marker in EOC. Our results show that high KIF20A protein expression correlates with tumor progression and may be viewed as a valuable prognostic factor of clinical outcomes in EOC.
There are many factors related to this poor prognosis in ovarian cancer, of which an important one is tumor progression. Drug resistance is an important reason for tumor progression. In most cases, ovarian cancer is one of the most treatable solid tumors at the early stage of treatment. However, ovarian cancer cells may develop drug chemoresistance during treatment, which causes further treatments to be ineffective and induce tumor progression. Ultimately, there is minimal improvement in OS of ovarian cancer patients during the past 30 years. 19 Even in the era of precision treatment, predicting the chemotherapy response and tumor progression of patients with EOC is extremely 
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Overexpression of kinesin family member 20a in epithelial ovarian cancer difficult. A platinum-based drug and a taxane were regarded as the first-line chemotherapy for advanced EOC patients. 20 Paclitaxel belongs to the family of antimitotic anticancer agents and blocks mitosis by stabilizing microtubules, leading to the blockage of cell division and therefore cell survival.
16
KIF20A is a microtubule-associated motor protein, and it plays the role of intracellular organelle transport and cell division . 17 Paclitaxel primarily disturbs mitotic spindle dynamics and triggers the mitotic checkpoint to induce extended G2/M arrest that can incur cell death via the intrinsic (mitochondrial) apoptotic pathway. 19 It is not difficult to surmise that high KIF20A expression correlates with chemoresistance. Additionally, in breast cancer, fork-head box M1-induced upregulation of KIF20A at transcriptional level confers drug resistance. 20, 22 Consistent with these reports, our findings provided evidence that overexpression of KIF20A strongly reduced the proportion of apoptosis cells, while knockdown of KIF20A obviously increased apoptosis cells compared with the control cells. Moreover, there are numerous mechanisms of drug resistance, involving the elevation of efflux mediated by P-glycoprotein coded by the ATP binding cassette subfamily B member 1 (MDR1/ABCB1) gene, spindle assembly checkpoint defects, mitotic slippage, activation of prosurvival signaling, and apoptosis evasion by modulating the activity of p53 and BCL2 family proteins. 21 However, the precise mechanisms by which KIF20A affects chemoresistance require further investigation.
From the intraperitoneal metastasis subgroup data, KIF20A expression was nearly three times that in the nonintraperitoneal metastasis subgroup. Intraperitoneal metastasis may be another independent prognostic factor associated with poorer outcomes in EOC. 20 In the majority of ovarian cancer cases, patients are always at an advanced stage, in which metastatic disease is already present, and detected, thus resulting in unfavorable prognosis. Unlike most solid tumors, EOC metastasis often occurs through the shedding of cancer cells from the ovarian tumor directly into the peritoneal cavity. 23 In addition, intraperitoneal metastasis may have an important role in the clinical staging of EOC according to FIGO 2014. Therefore, it is important to detect intraperitoneal metastasis at the early stages in EOC. 24 However, to date, there is lack of sensitive molecular biomarkers for detecting early intraperitoneal metastasis. 28 Our findings show that KIF20A expression correlates strongly with intraperitoneal metastasis in EOC. Additionally, Cox regression analyses showed that intraperitoneal metastasis is an important factor that shortens the OS of EOC. KIF20A expression in noncancerous ovarian tissue and primary ovarian cancer without intraperitoneal metastasis group was very low; however, ovarian cancer with intraperitoneal metastasis had remarkably high KIF20A expression. This suggests that KIF20A overexpression is related to intraperitoneal metastasis and poor outcome in EOC. Therefore, KIF20A can been seen as a biomarker for detecting intraperitoneal metastasis at the early stages of EOC and may contribute to improving survival of EOC patients. 24, 28 LN metastasis is another valuable prognostic factor of EOC 25 and is also an important factor for doctors to select suitable treatments. Clinically, the 5-year survival rate of EOC is >90% when the tumor is limited to the ovary; however, it decreases to only 30% when the metastasis has happened. 1 Patients with negative LNs have longer OS than patients with positive LNs. 26 Furthermore, detecting LN metastasis preoperatively can help doctors to determine whether there is a need for LN dissection. It contributes to the reduction of postoperative complications and to improving patients' quality of life. 27, 29 In our study, using univariate Cox regression analyses, we found that LN metastasis was a significant prognostic factor (P<0.001; Table 4 ). Therefore, detecting LN metastasis at the early stages may improve OS of EOC patients. However, currently, there are no markers for predicting LN status with high sensitivity and specificity. 30 Our findings show an obvious correlation between KIF20A overexpression with LN metastasis. Therefore, we suggest that KIF20A may be considered as a valuable biomarker for detecting LN metastasis in ovarian cancer. Thus, during further studies, a larger EOC cohort is needed to verify our results on LN metastasis, and the mechanism of KIF20A promoting LN metastasis of EOC should also be investigated.
Also, wound healing assay and transwell assay were used to evaluate the ability of migration and invasion of EOC cells. Our research shows that upregulation of KIF20A strongly enhanced migration and invasion abilities in EOC cells, but KIF20A-silenced cells obviously reduced migration and invasion. Angiogenesis is an important factor in the growth and invasion of malignant tumor. Vascular endothelial growth factor A (VEGF-A) belonging to VEGF family, plays an important role in angiogenesis, which is necessary for cell invasion and migration. 31, 32 The association between upregulation of VEGF-A and invasion has been reported in several cancers, including ovarian cancer. [33] [34] [35] [36] Exertier et al reported that KIF20A/MKLP2 combined with VEGF-A stimulates angiogenesis in vivo, and mitosis-independent vascular outgrowth was potently impaired by KIF20A inhibitor. 37 Collectively, we suggest that overexpression of KIF20A may enhance the ability of migration and invasion by regulating VEGF. Nevertheless, we should conduct further exploration to validate it.
Cancer immunotherapy has emerged recently as a promising means of treating cancer; consequently, researching and developing peptide vaccines targeting tumor-specific antigens is important. 38, 39 Several methods of EOC immunotherapy have been studied at present. 39 Moreover, antitumor immune responses by the immune system has been considered as a promising cancer treatment. Previous studies have shown that KIF20A has been used in immunotherapy for various cancers. Asahara et al performed an immunotherapy treatment that utilized KIF20A-66 cancer vaccine reagent, a human leukocyte antigen-A24-restricted epitope peptide obtained from KIF20A, which is significantly transactivated in pancreatic cancer, to treat pancreatic cancer. Patients who were vaccinated with KIF20A-66 had a better clinical outcome than the control group, and further clinical research using this peptide also achieved high potential benefit for patients in advanced 
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Overexpression of kinesin family member 20a in epithelial ovarian cancer stage of pancreatic cancer. 38 In immunotherapy of lung cancer and cholangiocellular carcinoma, a Phase I/II clinical trial is currently being carried out using KIF20A-derived short peptides. 40 Excitingly, Tomita et al reported that KIF20A long peptides (LP) stimulate KIF20A-specific cytotoxic T lymphocytes in vitro and in vivo. 40 KIF20A-specific T-helper type 1 (TH1) cell responses were investigated in head and neck cancer patients and then they received this immunotherapy (8/16, 50%). This finding reveals that the induction of KIF20A-specific TH1 cells in response to KIF20A-LP vaccination may promote the clinical response to chemotherapy or other standard therapies, such as radiotherapy or surgery. [41] [42] [43] Therefore, based on these previous studies, we believe that conducting research on KIF20A peptide-based immunotherapy of EOC is worthwhile. KIF20A may be a potential cancer therapeutic target to improve survival in EOC.
There are some limitations in our research. Firstly, our work was a retrospective study. Secondly, we performed migration, invasion, and chemoresistance related experiments in vitro, while we lacked some experiments in vivo to confirm our idea. But, in future experiments we will further conduct related in vivo experiments to verify our hypothesis and investigate the molecule mechanism.
Conclusions
In conclusion, our study provides convincing data that KIF20A is overexpressed in the majority of EOC tissues, and KIF20A expression could serve as an independent prognostic indicator for EOC patients. However, further examination of the molecular mechanisms behind the KIF20A-mediated potential tumorigenic effects in ovarian cancer is needed.
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